[go: up one dir, main page]

MXPA02012039A - Powder compositions. - Google Patents

Powder compositions.

Info

Publication number
MXPA02012039A
MXPA02012039A MXPA02012039A MXPA02012039A MXPA02012039A MX PA02012039 A MXPA02012039 A MX PA02012039A MX PA02012039 A MXPA02012039 A MX PA02012039A MX PA02012039 A MXPA02012039 A MX PA02012039A MX PA02012039 A MXPA02012039 A MX PA02012039A
Authority
MX
Mexico
Prior art keywords
drying
powder
compositions
prepared
spray
Prior art date
Application number
MXPA02012039A
Other languages
Spanish (es)
Inventor
Steven Joseph Prestrelski
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Publication of MXPA02012039A publication Critical patent/MXPA02012039A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

A gel-forming free-flowing powder suitable for use as a vaccine is prepared by spray-drying or spray freeze-drying an aqueous suspension that contains an antigen adsorbed to an aluminum salt or calcium salt adjuvant, a saccharide, an amino acid or a salt thereof, and a colloidal substance. Powder for vaccine purposes are also prepared by spray freeze-drying an aqueous suspension of such an adjuvant having an antigen adsorbed therein. Processes for forming these powder compositions are also described, as well as methods of using the compositions in a vaccination procedure.
MXPA02012039A 2000-06-08 2001-06-08 Powder compositions. MXPA02012039A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21058100P 2000-06-08 2000-06-08
US59077700A 2000-06-08 2000-06-08
PCT/US2001/018494 WO2001093829A2 (en) 2000-06-08 2001-06-08 Powder compositions

Publications (1)

Publication Number Publication Date
MXPA02012039A true MXPA02012039A (en) 2003-06-06

Family

ID=26905296

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012039A MXPA02012039A (en) 2000-06-08 2001-06-08 Powder compositions.

Country Status (11)

Country Link
EP (1) EP1289494A2 (en)
JP (1) JP2003535119A (en)
KR (1) KR20030020294A (en)
CN (1) CN1438874A (en)
AU (1) AU2001275371B9 (en)
BR (1) BR0111494A (en)
CA (1) CA2412197A1 (en)
IL (1) IL153241A0 (en)
MX (1) MXPA02012039A (en)
NZ (2) NZ552576A (en)
WO (1) WO2001093829A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2449593A1 (en) 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Spray freeze-dried compositions
KR20040073438A (en) * 2001-11-19 2004-08-19 벡톤 디킨슨 앤드 컴퍼니 Pharmaceutical compositions in particulate form
WO2003087339A2 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
DE10339197A1 (en) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried amorphous powder with low residual moisture and good storage stability
KR20070057954A (en) * 2004-09-28 2007-06-07 알자 코포레이션 Stabilization of Immune Activators with Alum-Adjuvant
WO2007002744A2 (en) * 2005-06-27 2007-01-04 Applied Thin Films, Inc. Aluminum phosphate based microspheres
EP2324850A1 (en) 2005-10-04 2011-05-25 Alk-Abelló A/S Solid vaccine formulation
EP1945249A2 (en) * 2005-11-01 2008-07-23 Novartis AG Compositions with antigens adsorbed to calcium phosphate
US20080226729A1 (en) * 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
US9017697B2 (en) 2006-10-12 2015-04-28 The University Of Queensland Compositions and methods for modulating immune responses
DK2829282T3 (en) * 2007-03-22 2018-01-02 Univ Colorado Regents Process for preparing an immunologically active adjuvant-linked dried vaccine composition
CN101801343A (en) * 2007-07-26 2010-08-11 圣诺菲·帕斯图尔有限公司 Antigen adjuvant compositions and methods thereof
AU2009221180B2 (en) 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
JP5701760B2 (en) 2008-10-02 2015-04-15 ファーマシーネ，インコーポレイテッド Anthrax vaccine preparation and its use
US9101607B2 (en) 2010-03-31 2015-08-11 Stabilitech Ltd. Method for preserving alum adjuvants and alum-adjuvanted vaccines
HUE033656T2 (en) 2010-03-31 2017-12-28 Stabilitech Ltd Excipients for stabilising viral particles
WO2011121306A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles
BR112013010926A2 (en) 2010-11-01 2016-08-23 Univ Technology Sidney immunomodulatory agents and their uses
EA201390812A1 (en) 2010-12-02 2013-11-29 Онколитикс Байотек Инк. LYOPHYLIZED VIRUS COMPOSITIONS
CA2819246C (en) 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
CN102133396B (en) * 2011-03-16 2013-10-16 中国人民解放军第三〇二医院 Vaccine injection and preparation method thereof
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
US12447127B2 (en) 2011-05-17 2025-10-21 The Regents Of The University Of Colorado, A Body Corporate Thermostable vaccine compositions and methods of preparing the same
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
EP2822540B1 (en) * 2012-03-05 2020-04-08 De Staat der Nederlanden, Vert. Door de Minister van VWS Methods and compositions for stabilizing dried biological materials
KR101441539B1 (en) * 2013-04-01 2014-09-18 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 Adhesive compositions having improved hygroscopicity and preparation methods thereof
CN103641886B (en) * 2013-11-26 2015-07-29 精晶药业股份有限公司 A kind of process for purification of glutamine dipeptide
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
GB202400295D0 (en) * 2024-01-09 2024-02-21 Stablepharma Ltd Hypertonic thermostable vaccine compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (en) * 1981-05-13 1982-11-19 Pasteur Institut IMPROVEMENTS IN LIVE STABILIZING AGENTS FOR THE PREPARATION OF VACCINES, AND STABILIZED VACCINES CONTAINING SAID STABILIZING AGENTS
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
JPS6013718A (en) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst B-type hepatitis vaccine
WO1994015363A1 (en) * 1992-12-28 1994-07-07 Yu Shih Chiang Non-volatile semiconductor memory cell
KR100291357B1 (en) * 1993-01-08 2001-09-17 터베이 피터. Vaccine formulation
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
RU2096042C1 (en) * 1996-11-06 1997-11-20 Виктор Иванович Ситьков Method of preparing multipartial vaccine for leptospirosis control in animals
HUP0101139A3 (en) * 1997-12-02 2003-11-28 Powderject Vaccines Inc Madiso Transdermal delivery of particulate vaccine compositions

Also Published As

Publication number Publication date
WO2001093829A2 (en) 2001-12-13
EP1289494A2 (en) 2003-03-12
NZ523103A (en) 2005-08-26
NZ552576A (en) 2008-06-30
AU2001275371B9 (en) 2007-06-07
CN1438874A (en) 2003-08-27
IL153241A0 (en) 2003-07-06
JP2003535119A (en) 2003-11-25
AU2001275371B2 (en) 2006-12-21
CA2412197A1 (en) 2001-12-13
BR0111494A (en) 2004-01-13
WO2001093829A3 (en) 2002-06-13
AU7537101A (en) 2001-12-17
KR20030020294A (en) 2003-03-08

Similar Documents

Publication Publication Date Title
MXPA02012039A (en) Powder compositions.
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
Tagliabue et al. Vaccine adjuvants: the dream becomes real
ES2313881T3 (en) FORMULATIONS OF VACCINES FRONT OF THE HUMAN PAPILOMAVIRUS.
GB0118249D0 (en) Histidine vaccines
JP2002501904A (en) vaccine
EP2368573A3 (en) Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
RU2004122632A (en) LYOPHILIZED DRUG CONTAINING ANTIBODIES AGAINST EGF RECEPTOR
JP2000502672A (en) Live vaccine stabilizer
WO2000023105A3 (en) Adjuvant systems and vaccines
WO2004001007A3 (en) Buffered formulations for concentrating antibodies and methods of use thereof
CA2282779A1 (en) Formulation comprising an antigen, an adjuvant and an amino acid for use in immunization.
IL316312A (en) Formulations of dengue virus vaccine compositions
PT1409692E (en) Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine
AU2011234268B2 (en) Method for preserving alum adjuvants and alum-adjuvanted vaccines
Colombani et al. Biomaterials and oxygen join forces to shape the immune response and boost COVID‐19 vaccines
SG179406A1 (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
JP2004505992A5 (en)
RU2014151424A (en) THERMOSTABLE VACCINE COMPOSITIONS
WO2004073652A3 (en) Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
JP2017509713A5 (en)
WO2002036160A3 (en) Method for obtaining antigenic structures enhancing specific cross reactivity
WO2023235660A3 (en) Flavivirus immunogens and vaccine compositions and methods of using the same
ATE476195T1 (en) DELAYED RELEASE PREPARATIONS OF PRO-INSULIN C PEPTIDE

Legal Events

Date Code Title Description
FG Grant or registration